Protective Efficacy of Baculovirus Dual Expression System Vaccine Expressing *Plasmodium falciparum* Circumsporozoite Protein

Mitsuhiro Iyori¹, Hiroki Nakaya¹, Katsuya Inagaki², Sathit Pichyangkul³, Daisuke S. Yamamoto⁴, Masanori Kawasaki², Kyungtak Kwak², Masami Mizukoshi², Yoshihiro Goto², Hiroyuki Matsuoka⁴, Makoto Matsumoto², Shigeto Yoshida¹*

1 Laboratory of Vaccinology and Applied Immunology, Kanazawa University School of Pharmacy, Kanazawa, Japan, 2Microbiological Research Institute, Otsuka Pharmaceutical Co. Ltd., Tokushima, Japan, 3Department of Immunology and Medicine, USAMC-AFRIMS, Bangkok, Thailand, 4Division of Medical Zoology, Department of Infection and Immunity, Jichi Medical University, Tochigi, Japan

Abstract

We have previously developed a new malaria vaccine delivery system based on the baculovirus dual expression system (BDES). In this system, expression of malaria antigens is driven by a dual promoter consisting of the baculovirus-derived polyhedrin and mammal-derived cytomegalovirus promoters. To test this system for its potential as a vaccine against human malaria parasites, we investigated immune responses against the newly developed BDES-based *Plasmodium falciparum* circumsporozoite protein vaccines (BDES-PfCSP) in mice and Rhesus monkeys. Immunization of mice with BDES-PfCSP induced Th1/Th2-mixed type immune responses with high PfCSP-specific antibody (Ab) titers, and provided significant protection against challenge from the bites of mosquitoes infected with a transgenic *P. berghei* line expressing PfCSP. Next, we evaluated the immunogenicity of the BDES-PfCSP vaccine in a rhesus monkey model. Immunization of BDES-PfCSP elicited high levels of anti-PfCSP Ab responses in individual monkeys. Moreover, the sera from the immunized monkeys remarkably blocked sporozoite invasion of HepG2 cells. Taken together with two animal models, our results indicate that this novel vaccine platform (BDES) has potential clinical application as a vaccine against malaria.

Citation: Iyori M, Nakaya H, Inagaki K, Pichyangkul S, Yamamoto DS, et al. (2013) Protective Efficacy of Baculovirus Dual Expression System Vaccine Expressing *Plasmodium falciparum* Circumsporozoite Protein. PLoS ONE 8(8): e70819. doi:10.1371/journal.pone.0070819

Editor: Laurent Renia, Agency for Science, Technology and Research - Singapore Immunology Network, Singapore

Received February 25, 2013; Accepted June 22, 2013; Published August 12, 2013

Copyright: © 2013 Iyori et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported in part from a Grant-in-Aid for Young Scientists from the Hokuriku Bank, Ltd. (http://www.hokuhoku-fg.co.jp/english/) and Grants-in-Aid for Scientific Research (B) (JSPS KAKENHI Grant Number 21390126) (http://www.jsps.go.jp/english/e-grants/index.html), grants from the Waksman Foundation (http://www.waksman.or.jp/) and Otsuka Pharmaceutical Co. Ltd. (http://www.otsuka.co.jp/en/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: KI, M.K., K.K., M.M., Y.G., and M.M. are employees of Otsuka Pharmaceutical, whose company provided funding towards this study. For malaria vaccine developments, there are products in development related to this manuscript. Therefore, similar to RTS,S malaria vaccine, there are some limitations on sharing materials. The authors would greatly appreciate the reader’s understanding for encouraging the malaria vaccine development.

* E-mail: shigeto@ip.kanazawa-u.ac.jp

Introduction

Malaria is one of the world’s most devastating infectious diseases and is a major killer of children under five years old in Africa. The World Health Organization estimates that malaria transmission is present in 98 countries, and that the disease causes 216 million clinical cases each year and 655,000 deaths [1]. The most advanced malaria vaccine candidate, RTS,S/AS01, a *Plasmodium falciparum* circumsporozoite protein (PfCSP)-based vaccine containing the specific adjuvant AS01 was developed many years ago [2]. This vaccine is based on an N-terminal truncated form of PfCSP, which is fused to the hepatitis B surface antigen on the virus-like particle (VLP) platform [3,4]. The hybrid malaria-hepatitis B VLP is available lyophilized and undergoes point-of-use reconstitution with GlaxoSmithKline’s AS01 adjuvant [3,5]. The first Phase III trial of RTS,S/AS01 in African children reported approximately 50% efficacy against clinical and severe malaria in children 5 to 17 months of age, but a recent study reported lower efficacy (around 30%) in infants 6 to 12 weeks of age, an outcome that clearly needs to be improved [6,7]. Although improvement of vaccine efficacy is urgently needed, rapid advancements in this goal may not be so easy because the protective immune mechanism of the RTS,S/AS01 is not fully understood. Thus, new and more effective vaccine delivery systems are urgently needed for malaria vaccines.

Recently, interest in an insect-infesting baculovirus has focused on its potential use as a vaccine and gene therapy vector [8,9]. Thanks to its biosafety, low cytotoxicity, non-replication in transduced mammalian cells and an absence of preexisting antibodies (Abs) against it in humans, baculovirus has emerged as a novel gene delivery vector [8,9]. Because the virus can induce innate immune responses in host cells, it has been well characterized as an adjuvant-free vaccine platform [10,11]. This well-developed vaccine system can deliver the antigens of interest by several unique methods; for example, (i) the desired antigen can be expressed by the vector within host cells in a manner similar to DNA vaccines; (ii) the desired antigen can be displayed on the surface of the baculovirus, or (iii) the desired antigen can be expressed and displayed by the vector [8,12].
We have developed a "baculovirus dual expression system (BDES)" that drives malaria antigen expression by a dual promoter that consists of both baculovirus-derived polyhedrin and mammal-derived cytomegalovirus (CMV) promoters [13–16]. This system is very effective as an all-stage malaria vaccine platform. For pre-erythrocytic-stage parasites, the rodent malaria sporozoite BDES vaccine (AcNPV-Dual-PbCSP) provided 100% protection against infection in the P. berghei-infected BALB/c rodent malaria model [13]. In addition, baculovirus vectors displaying the P. yoelii blood-stage antigens, merozoite surface protein 1 (PyMSP1 19) and apical membrane antigen 1 (PyAMA1) conferred complete protection against P. yoelii rodent malaria [14,15]. For the mosquito transmission-stage, BDES was utilized for expression of the transmission-blocking antigens Pfs25 and Pvs25 in the vaccines against the sexual stages of the parasites, which induced strong transmission-blocking responses by challenge using a transgenic P. berghei line expressing Pfs25 and Pvs25, respectively [16,17].

In the present study we constructed a new BDES for expression of P. falciparum CSP (BDES-PfCSP). BDES-PfCSP elicited protective immune responses against PfCSP-transgenic parasites in mice, as evaluated by the level of protection conferred against sporozoite challenge infections. To advance this system for clinical use, we investigated the immune responses to this new vaccine in rhesus monkeys. BDES-PfCSP provided high levels of anti-PfCSP Abs with strong inhibitory activities against sporozoite invasion into HepG2 cells. Our results show the potential of this novel vaccine platform for application as a vaccine against malaria.

Materials and Methods

Ethics Statement

All animal care and handling procedures were approved by the Animal Care and Use Committee of Kanazawa University (No. 22118–1) and the Guidelines for Animal Care and Use prepared by Jichi Medical University (No. 09193). The non-human primate study was conducted in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals and adhered to the principles stated in the Guide for the Care and Use of Laboratory Animals, NRC Publication, 1996 edition. Monkeys were housed individually in standard squeeze-type stainless steel cages at a minimum floor space of 4.4 square feet. Cages were cleaned daily and sanitized biweekly. Monkeys were fed complete, commercially prepared monkey chow twice daily and mixed fresh vegetables and fruits at least four times per week. Chlorinated water was provided ad libitum via automatic watering valves. Animals participated in the nonhuman primate enrichment program in accordance with AFRIMS’s SOP. All monkeys were given 5–20 mg/kg ketamine hydrochloride intramuscularly for anesthesia before blood was collected or animals were vaccinated. Monkeys were not sacrificed. At the conclusion of the study, animals were released.
from the protocol and back to the colony. All efforts were made to minimize suffering in the animals.  

Recombinant viral vaccines  
To construct pTriEX-Dual-PfCSP-Tcell, the gene encoding amino acids 19–373 of PfCSP (i.e., lacking the N-terminal signal peptide and C-terminal glycosylphosphatidylinositol anchor sequences) was PCR amplified from *P. falciparum* 3D7 genomic DNA, and the resulting fragment was inserted into EcoRI/Xma I cut pTriEX-Dual-PbCSP [13]. To construct the plasmids of pCAP-CO-PfCSP-full and pCAP-CO-PfCSP-205, DNA sequences encoding PfCSP were synthesized to optimize codon usage in mammalian cells. All PfCSP sequences were modified to introduce a point-mutation where alanine at position of 361 was substituted with glutamic acid; this incorporated an H-2Kk-restricted CD8 encoded epitope peptide into the constructs. Generation of recombinant baculoviruses and purification of baculovirus particles were conducted as described previously [13,14]. To generate the adenoviral vector Adeno-COE/1–373, CMV promoter sequences, followed immediately by the gene encoding the full-length PfCSP were subcloned into pAd/PL-DEST (Invitrogen, Carlsbad, CA); viral purification and viral particle (VP) titrations were carried out according to the manufacturer’s protocol. All other viral-related methods used herein are described in Materials and Methods S1.  

Immunizations  
Balb/c mice were immunized intramuscularly three times at 3-week intervals with 10^8 plaque forming units (PFU) of BDES-PfCSP, AcNPV-Dual-PbCSP or wild-type AcNPV (AcNPV-WT). A different group of mice were immunized twice at 3-week intervals with 10^10 VP of the Adeno-COE/1-373 vaccine.  
Malaria naive rhesus monkeys were selected and randomized into 6 groups. Each group was immunized intramuscularly, subcutaneously, or intradermally three times at 4-week intervals with 3 × 10^9 PFU of BDES-PfCSP or AcNPV-WT.  

PF CSP-Tc/Pb sporozoite challenge  
Anopheles stephensi mosquitoes (SDA 500 strain) were infected with PICSP-Tc/Pb [Materials and Methods S1, [18]] by allowing them to feed on parasite-infected mice (Fig. S1). The condition of the parasites (in terms of their infectivity) to recipient mice was checked by exflagellation tests before blood feeding commenced. The sporozoite-positive rate in the salivary glands of the mosquitoes used for the challenge infections was over 58%. Two weeks after the third immunization, the mice were challenged by blood feeding with parasite-infected mosquitoes. For the challenge infections (via natural biting), three to seven mosquitoes were allowed to feed on the abdomen of each mouse for 20 minutes. The salivary glands from all blood-engorged mosquitoes in the PBS control group were dissected to confirm the presence of sporozoites. Where necessary, mosquito feeds were repeated with fewer mosquitoes until three to seven infected mosquitoes had bitten all of the mice.  

Statistical analysis  
The Mann-Whitney U test and the Kruskal-Wallis non-parametric analysis were used to compare Ab titer levels. The Dunnett two-tailed *t*-test and the two-tailed Fisher’s exact probability test were used to determine statistical differences in the protective efficacy of BDES. In all other experiments, statistical differences between the experimental groups were analyzed using the Student’s *t*-test; *p* values < 0.05 were considered statistically significant.
significant. Statistical analyses were performed using SPSS Statistics (version 19, IBM) and Prism version 5 (GraphPad Software Inc.).

**Results**

Construction of a baculovirus dual expression system for PfCSP

Three types of BDES for heterologous expression of PfCSP genes (BDES-PfCSP) were constructed (Fig. 1A). The construct designated “CMV-full” harbored a gene cassette consisting of the gp64 major envelope protein signal sequence and the gene encoding PfCSP19–373 fused to the N-terminus of AcNPV gp64, which was driven by the CMV \( \text{ie} \) /polyhedrin dual promoter. The “CAG-full” vaccine construct was designed to express the codon-optimized PfCSP1–397 gene cassette under the control of the CAG/polyhedrin dual promoter. The “CAG-205” vaccine construct designed to express the codon-optimized PfCSP205–373 is an N-terminal truncated form of PfCSP, which is similar to the target sequence of the RTS,S vaccine [19].

**PfCSP expression in the BDES system**

Western blotting showed that the anti-PfCSP mAb 2A10 recognized PfCSP expressed by CMV-full, CAG-full and CAG-205 constructs (Fig. 1B). The relative molecular mass of CMV-full was about 127 kDa, which is slightly bigger than that of CAG-full, whereas CAG-205 was around 85 kDa (Fig. 1B). Densitometry showed that the quantities of the PfCSP antigens displayed on CAG-full and CAG-205 were over 4-fold and 8-fold higher than that of CMV-full, respectively, when normalized against the viral protein VP39 using anti-VP39 polyclonal Abs (Fig. 1B).

To examine the ability of BDES vaccines to drive PfCSP expression in mammalian cells, COS-7 and HepG2 cells were transduced using purified baculovirus BDES particles. Blossom-like PfCSP expression was detected on both COS-7 and HepG2 cells exposed to CAG-full, CAG-205 and CMV-full, and the transduction efficacies of CAG-full and CAG-205 were clearly superior to that of CMV-full (Fig. 1C); this result might be due to codon-optimization of CAG-full and CAG-205. No signal was detected from the cells transfected with AcNPV-WT (Fig. 1C).

**Induction of anti-PfCSP Ab responses in mice using BDES-PfCSP**

Three separate immunizations with BDES-PfCSP increased the anti-PfCSP total IgG titers in immunized mice (Fig. 2A). After the second booster immunization, the Abs titer against PfCSP significantly increased compared with that observed after the initial immunization, resulting in a 7.1- to 21.7-fold rise in the mean titer values (Fig. 2A). The booster effects of the third immunization were lower, but increased by 1.3- to 4.4-fold
Laser scanning microscopy PfCSP expression in transgenic \textit{P. berghei} Salivary glands from the infected mosquitoes as well as transgenic visualized by DAPI (blue). Bar = 50 μm. Alexa Flour 594 (red). Parasite nuclei and mosquito salivary glands were probed with the 2A10 mAb conjugated to \textit{P. berghei} immunized mice.

Figure 4. PfCSP expression in transgenic \textit{P. berghei}. (A) Confocal laser scanning microscopy PfCSP expression in transgenic \textit{P. berghei}. Salivary glands from the infected mosquitoes as well as transgenic \textit{P. berghei} sporozoites were probed with the 2A10 mAb conjugated to Alexa Flour 594 (red). Parasite nuclei and mosquito salivary glands were visualized by DAPI (blue). Bar = 50 μm. (B) Salivary glands from uninfected mosquitoes or mosquitoes infected with the transgenic parasites were lysed and loaded onto 10% gels, and then immunobotted with the 2A10 mAb and anti-AAPP mAb (28B8).

(Fig. 2A). In agreement with the amounts of PICSP expressed on the BDES particles, the mean Ab titers ± standard deviations (SD) after the third immunization with CMV-full, CAG-full and CAG-205 were 12,053 ± 8370, 40,433 ± 28,480, and 303,333 ± 139,215, respectively (Fig. 2A). Antibody subclass analysis showed that BDES-PICSP induced not only IgG1 but also IgG2a and IgG2b respectively (Fig. 2A). Antibody subclass analysis showed that parasites in the mosquito salivary glands expressed PICSP as a triplet of bands with relative molecular masses of around 50 kDa (Fig. 4B), which may correspond to precursor and mature forms of the protein, as previously reported [22]. We also confirmed that non-infected salivary glands did not react with the 2A10 mAb, but the mosquito saliva protein AAPP, which was used as an internal control, was expressed in infected and non-infected salivary glands (Fig. 4B) [23].

Two weeks after the third immunization with BDES vaccines, the mice were challenged by the bites of PICSP-Tc/Pb-infected mosquitoes. Malaria is transmitted by the bite of an infected mosquito and this method of transmission has been used in challenge infections in human clinical trials [24–27]; this method of transmission was used in the present study. BDES-PICSP was compared with the non-immunized group for its protective efficacy. In some experiments, AcNPV-Dual-PbCSP (a PbCSP vaccine that provided 100% protection against wild-type \textit{P. berghei} [13]), AcNPV-WT (wild-type baculovirus control for vector-related responses), or Adeno-COE/1–373 were used as immunization controls (Table S1). Significant protective efficacy was observed in the mice immunized with CMV-full (20.0%), CAG-full (26.2%) and CAG-205 (30.4%), but AcNPV-Dual-PbCSP did not confer any protection, indicating that the protective efficacy was antigen-specific (Table 1). In addition, the Adeno-COE/1–373 vaccine induced strong CD8+ T cell responses (Fig. 3A, B), but none of the immunized mice were protected. As observed by ourselves and other groups previously, not all of the mice in the non-immunized groups were infected because of the large variation in the numbers of sporozoites injected by individual mosquitoes [13,28,29]. Noticeably, five days after the challenge infections, almost all (>90%) of the mice immunized with BDES-PICSP were uninfected, whereas 60% to 70% of those in the control groups were infected (Table 1). The vaccine delayed parasitemia could result in a reduction of parasite loads during both the liver and erythrocytic stages of the parasites. As hypothesized, BDES-PICSP vaccines provided a significant reduction of the parasitemia 5 to 7 days after the challenge (Fig. 5A, B), but this reduction had abated at day 9 after the challenge (Fig. 5C). Notably, reduction of the parasitemia in the BDES-PICSP immunized mice ranged from 87.1% to 100% at day 5 and 55.4% to 76.3% at day 7 as compared with that of the PBS control group, indicating that immunization with BDES-PICSP led to delays of PICSP-Tc/Pb-infection during the early
stages of infection (Fig. 5A, B). If the parasitemias of the non-infected mice (0%) were removed from the calculation, only the day 7 parasitemia of the CAG-205 group was significantly reduced as compared with the control group, but those of the other groups were not (data not shown). The higher Ab titers against PfCSP slightly reduced the day 7 parasitemia (Fig. S2A), and there was no threshold level of anti-PfCSP titer required for complete protection (Fig. S2B, C). Similar to the anti-PfCSP titer, anti-NANP Abs were not correlated with the protective efficacy of BDES-PfCSP (Fig. S2D–F). Taken together, although the BDES vaccines delayed the appearance of blood stage parasitemia, the protective efficacy of the vaccines had no clear correlation with the anti-PfCSP Ab titers or with the anti-NANP titers.

Figure 5. Parasitemia in the immunized mice after parasite challenge. Giemsa-stained thin smears of tail blood were prepared at days 5, 7 and 9 after challenge. The percentage parasitemias and parasitemia reduction rates in the individual mice were compared with those from the PBS-control mice using the following formula: % reduction = [1 – (% parasitemia of immune group)/(% parasitemia of PBS group)]*100. Data from 3 independent experiments were pooled (n = 40), except for the CMV-full group (n = 15).

doi:10.1371/journal.pone.0070819.g005

Table 1. Vaccine protection levels in mice immunized with different BDES constructs following challenge infections administered by the bites of mosquitoes infected with PfCSP-Tc/Pb.

| Vaccine            | Delayed parasitemia: no. of uninfected mice/total no. (%)a | Complete protection: no. of protected mice/total no. (%)b | % of mice protecteda |
|--------------------|-----------------------------------------------------------|----------------------------------------------------------|----------------------|
|                    | 5 days  | 7 days  | 9 days  |                                            |                              |                               |
| PBS                | 26/40 (65) | 8/40 (20) | 7/40 (18) | 7/40 (18)c | 0.0 |
| AcNPV-WT           | 9/15 (60)  | 1/15 (7)   | 1/15 (7)   | 1/15 (7)   | 0.0 |
| AcNPV-Dual-PbCSP   | 7/10 (70)  | 0/10 (0)    | 0/10 (0)    | 0/10 (0)   | −11.1 |
| Adeno-COE/1-373    | 8/10 (80)  | 2/10 (20)   | 0/10 (0)    | 0/10 (0)   | −11.1 |
| CMV-full           | 15/15 (100) | 8/15 (53)  | 7/15 (47)  | 7/15 (47)d | 20.0 |
| CAG-full           | 36/40 (90) | 21/40 (53) | 16/40 (40) | 16/40 (40) | 26.2 |
| CAG-205            | 38/40 (95) | 25/40 (63) | 19/40 (48) | 19/40 (48)d | 30.4 |

*aMice were screened for PfCSP-Tc/Pb blood-stage infections by microscopic examination of Giemsa-stained thin smears of tail blood prepared at days 5, 7, 9 and 14 after challenge infections from PfCSP-Tc/Pb-infected mosquitoes (3 mosquitoes/7/mouse). After the appearance of parasites in the blood, all of the mice died.

*bComplete protection is defined as the complete absence of blood-stage parasitemia on day 14 post-challenge.

*cumulative data from three independent experiments (Exp. 1, 2 and 3 in Table S1).

*dEach group of immunized mice were compared with the non-immunized group (PBS) to test for statistically significant differences using Fisher’s exact probability test.

*eVaccine efficacy was calculated using the formula: Efficacy = [1–(number of infected animals (vaccine)/total number of animals (vaccine))–(number of infected animals control (0)/total number of animals (n) control)]*100. Mean efficacies from three independent studies are shown.

doi:10.1371/journal.pone.0070819.t001
with CAG-205, 98.4% with CAG-205 by i.d. and 99.9% with CAG-full by i.m.; in most cases these values were higher than that of the purified 2A10 mAb (97.9%). Consistent with the murine model, CAG-full-immunization of the monkeys induced low Abs titers; however, sporozoite invasion was effectively inhibited and was as high as that achieved with the CAG-205-immunizations. The present data show that all immunization routes induced high Abs responses, and that i.m. and i.d. routes were particularly effective at inhibiting sporozoite invasion.

Discussion

In this study, we have shown that PfCSP-based baculovirus vaccines induced protective immunity against PICSP-Tc/Pb transgenic parasites in mice, and that the antibodies induced in primates markedly inhibited sporozoite invasion of HepG2 cells. Enhancement of the PICSP gene by codon-optimization to facilitate expression in mammalian cells clearly enhanced its expression levels in viral particles and transduced cells, leading to strong induction of humoral immunity. A principal aim when developing CSP-based vaccines is the induction of high levels of CSP Abs in the host [2,30]. The present study, however, found that although the anti-PICSP Ab titer in the CAG-205-immunized mice was over 8-fold higher than that of the CAG-full-immunized mice, the protection level for CAG-205 (30.4%) was not significantly different from that of CAG-full (26.2%). Many studies have reported that Abs against the NAMP-repeat sequence in PICSP can neutralize sporozoites and reduce their infectivity [20,30-32]. Because anti-NANP Ab titers in the immunized groups were over 10-fold lower than the anti-PICSP titers, most anti-PICSP Abs induced by BDES appear to afford less protection against the parasites. Conversely, the CAG-full construct provided significant protection despite lower Ab titers, indicating the importance of the N-terminal region of PICSP in protective immunity. Past studies on sporozoite vaccines have revealed a poor correlation between the protective efficacy of a vaccine and antibody titers. For examples, the complement fragment C3d-based PbCSP vaccine was capable of inducing strong antibody responses against CSP, but its protective efficacy, compared with the parent PbCSP vaccine, was reduced [33]. Studies in our laboratory are in progress towards development of an evaluation system which can detect the specific antibodies that contributed to the protective efficacy of a vaccine.

CD8+ T cells are thought to be the critical determinants of irradiated sporozoite immunity in both mice and primates [34-36]. The available evidences of an absence of substantial PICSP-specific CD8+ T cell responses in RTS,S clinical trials strongly supports anti-PICSP antibodies as playing a more important role in RTS,S-mediated protection than cell-mediated immunity [2]. Since BDES is designed to function not only as a VLP but also as a DNA vaccine induction of both humoral and cellular immune responses are expected. Indeed, our previous study showed that AcNPV-Dual-PbCSP could induce not only high anti-PbCSP Ab titers but also a high frequency of IFN-γ-producing T cells specific for PfCSP [13]. As BDES-PICSP provided a mixture of Th1/Th2 immune responses (Fig. 2B), the type of immune responses induced by BDES were clearly different from that of protein-based component vaccines [15], indicating that BDES can induce both humoral and cellular immunity. In the present study, however, we could not detect anti-PICSP specific T cell-responses in the BDES-immunized mice. In addition, the CAG-205 vaccine, which induced the strongest anti-PICSP Ab titers and protective efficacy, lacked the N-terminal sequence comprising the H-2Kd-restricted T cell epitope [21]. Two studies have shown that adenoviral vectors expressing PICSP can induce CSP epitope-specific IFN-γ T cells, but the involvement in protective efficacy of such T cells remains unclear [37,38]. In the present study, immunization with the Adeno-COE/1-373 adenoviral vaccine induced high IFN-γ CD8+ T cell responses via stimulation by the PICSP epitope (Fig. 3A, B), but none of the immunized mice were protected (Table 1). Consistent with our data, the Phase 1/2a clinical trial of the adenovirus-5-based vaccine encoding PICSP reported that even though robust PICSP-specific CD8+ T cell responses were induced, the vaccine did not steriley protect volunteers against challenge via the bites of infected mosquitoes, which is the same challenge route as was used here [39]. To determine whether PICSP epitope-specific T cells induce protective immunity in a mouse malaria model, further study is necessary to identify the role of the cytotoxic T cells during infection with PICSP-Tc/Pb; this could be approached by using epitope-specific immunization models such as the CS epitope-pulsed dendritic cell injection model.

The present study demonstrated that BDES vaccines could induce strong anti-PICSP Ab titers (in a primate immunization model) and that such antibodies blocked sporozoite invasion of HepG2 cells (Table 2). For BDES to be used as a vaccine in clinical settings it is important to assess its biosafety in a primate model of malarial disease. Rhesus monkeys have been used as very useful predictors of vaccine safety, immunogenicity and protective immunity. Past studies on sporozoite vaccines have revealed a poor correlation between the protective efficacy of a vaccine and antibody titers. For examples, the complement fragment C3d-based PbCSP vaccine was capable of inducing strong antibody responses against CSP, but its protective efficacy, compared with the parent PbCSP vaccine, was reduced [33]. Studies in our laboratory are in progress towards development of an evaluation system which can detect the specific antibodies that contributed to the protective efficacy of a vaccine.
The *P. berghei* introduces the *pfcsp-Tcell* (A361E) was replaced with that of *PbCSP*. UTILITY of the *pbcsp* DHFR-3 line. Schematic representation of pBS-5

**Figure S1** Generation of the PfCSP-Tc/Pb transgenic parasite line. Schematic representation of pBS-5’ UTR-PfCSP-Tcell-DHER-3’ UTR, the DNA construct used for integration into the *P. berghei* genome. This construct disrupts the *pfcsp* gene and introduces the *pfcsp-tcell* gene under the control of the 5’ and 3’ UTR of the *pfcsp* gene. The signal peptide sequence of PICSP-Tcell (A361E) was replaced with that of PfCSP.

### Supporting Information

**Figure S2** Relationship between PICSP-specific Ab titer and protective immunity. (A) Correlation between anti-PICSP Ab titer and parasitemia at day 7 in mice immunized with CMV-full, CAG-full and CAG-205. (Spearman’s rank correlation; *r* = −0.15; *p* = 0.133) (B) The Ab titers against PICSP in the sera from either infected mice (black) or protected mice (white) were shown. (C) Mean Ab titers ± S.D. of (B). (D) Correlation between anti-NANP Ab titer and parasitemia at day 7 in mice immunized with CMV-full, CAG-full and CAG-205 (Spearman’s rank correlation; *r* = 0.070; *p* = 0.498). (E) The Ab titers against NANP in the sera from the infected mice (black) or protected mice (white) are shown. (F) Mean Ab titers ± S.D. of (E). Data from 3 independent experiments were pooled (n = 40 for CAG-full and CAG-205, and n = 15 for CMV-full).

(TIF)

**Figure S3** ELISA conditions used in this study. (A) ELISA plates were coated with either rPICSP or NANP peptides. The anti-PICSP mAb 2A10 was serially diluted and applied to the wells. Mean values ± S.D. from quadruplicate wells are shown. (B) Mean ± S.D. of the 2A10 concentration at the end point. (OD414 = 0.15) at (A). (C) Serum from a naive mouse was collected and examined by ELISA using the rPICSP and the NANP repeat. (D) Mean ± S.D. of end point dilution at (C).

**Materials and Methods S1.**

(DOC)

**Table S1** Immunization groups of animals with BDES vaccines.

(DOC)

**Table S2** Condition of the PICSP-Tc/Pb infection in mice.C.

(DOC)

### Acknowledgments

We thank C. Seki for excellent assistance making Giemsa-stained thin blood smears. We also thank A. Sawaguchi, T. Funatsu, S. Ogata, H. Nishiura, S. Matsuhita and M. Mizutani for assistance with animal care. The views expressed in this article are those of the authors’ and do not reflect those of the U.S. Department of the Army, U.S. Department of Defense, or the U.S. Government.

### Author Contributions

Conceived and designed the experiments: MI,SP. Matsumoto SY. Performed the experiments: MI,HN,DY. Analyzed the data: MI,SY. Contributed reagents/materials/analysis tools: MI,HN,KI,SP,DY,MI,MK.KK. M. Mizukoshi YG HM M. Matsumoto SY. Wrote the paper: MI,SY.

### References

1. (2011) World malaria report 2011. World Health Organization.
2. Crompton PD, Perce SR, Miller LH (2010) Advances and challenges in malaria vaccine development. J Clin Invest 120: 4166–4176.
3. Moorthy VS, Balouo VR (2009) Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar J 8: 312.
4. Garcon X, Heppner DG, Cohen J (2003) Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev Vaccines 2: 231–238.
5. Reed SG, Bertholet S, Coffer RN, Friede M (2009) New horizons in adjuvants for vaccine development. Trends Immunol 30: 23–32.
6. Agnandji ST, Leil B, Soulasoudjingu SS, Fernandes IF, Abososo BP, et al. (2011) First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 365: 1863–1875.
7. Agnandji ST, Leil B, Fernandes IF, Abososo BP, Methigo BNGO, et al. (2012) A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. N Engl J Med.
8. Chen GY, Lin CY, Chen GY, Hu YC (2011) Baculovirus as a gene delivery vector: recent understandings of molecular alterations in transduced cells and latest applications. Biotechnol Adv 29: 618–631.
9. Lu HY, Chen YH, Liu HJ (2012) Baculovirus as a vaccine vector. Bioengineered 3.
10. Abe T, Matsuura Y (2010) Host innate immune responses induced by baculovirus in mammals. Curr Gene Ther 10: 226–231.
11. Strauss R, Hauser A, Ni S, Turv S, Kiviat N, et al. (2007) Baculovirus-based vaccination vectors allow for efficient induction of immune responses against plasmid falciparum circumsporozoite protein. Mol Ther 15: 193–202.
12. Yoshida S, Kawasaki M, Hariguchi N, Hirota K, Matsumoto M (2009) A baculovirus dual expression system-based malaria vaccine induces strong protection against Plasmodium berghei sporozoite challenge in mice. Infect Immun 77: 1782–1789.
14. Yoshioka S, Nagumo H, Yokomine T, Araki H, Suzuki A, et al. (2010) Plasmodium berghei Circ um vitens Immune Responses Induced by Merozoite Surface Protein 1- and Apical Membrane Antigen 1-Based Vaccines. PLoS One 5: e13727.

15. Yoshioka S, Araki H, Yokomine T (2010) Baculovirus-based nasal drop vaccine confers complete protection against malaria by natural boosting of vaccine-induced antibodies in mice. Infect Immun 78: 595–602.

16. Blagborough AM, Yoshioka S, Sattabongkot J, Tsatsi T, Sinden RE. (2010) Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvr25 vaccine substantially blocks Plasmodium vivax transmission. Vaccine 28: 6014–6020.

17. Mlambi G, Kumar N, Yoshioka S (2010) Functional immunogenicity of baculovirus expressing Pvr25, a human malaria transmission-blocking vaccine candidate antigen. Vaccine 28: 7025–7029.

18. Sumitani M, Kasahima K, Yamamoto D, Yagi K, Yuda M, et al. (2012) Reduction of malaria transmission by transgenic mosquitoes expressing an anti-sporozoite antibody in their salivary glands. Insect Molecular Biology in press.

19. Gordon DM, McGovern TW, Kraych E, Cohen JC, Schneider I, et al. (1995) Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 171: 1357–1363.

20. Guinevart C, Aponte JJ, Sacarlal J, Ade P, Leach A, et al. (2009) Insights into long-lasting protection induced by RTS,S/A02A malaria vaccine: further results from a phase Ib trial in Mozambican children. PLoS One 4: e3165.

21. Blum-Tirouvanziam U, Beghdadi-Rais C, Roggero MA, Valmori D, Bertholet S, et al. (2009) Insights into long-lasting protection induced by RTS,S/A02A malaria vaccine: further results from a phase Ib trial in Mozambican children. PLoS One 4: e3165.

22. Coppi A, Pinzon-Ortiz C, Hutter C, Sinnis P (2005) The Plasmodium yoelii sporozoite protein is proteolytically processed during cell invasion. J Immunol 175: 4134–4141.

23. Yoshioka S, Sudo T, Niimi M, Tao L, Sun B, et al. (2008) Inhibition of collagen-induced platelet aggregation by anaphylone antplatelet protein, a salvia protein from a malaria vector mosquito. Blood 111: 2007–2014.

24. Dunachie SJ, Walterh M, Epstein JE, Keating S, Bertholet T, et al. (2006) A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect Immun 74: 3943–3949.

25. Fashine A, Valante NM, Ulmer JB. (2005) Targeting the innate immune response with improved vaccine adjuvants. Nat Med 11: 563–68.

26. Webster DP, Dunachie S, Vuola JM, Bertholet T, Keating S, et al. (2005) Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant parasite FP9 and modified vaccinia virus ankara. Proc Natl Acad Sci U S A 102: 4836–4841.

27. Church LW, Le TP, Bryan JP, Gordon DM, Edelman R, et al. (1997) Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J Infect Dis 175: 915–920.

28. Medica DL, Sinnis P. (2005) Quantitative dynamics of Plasmodium yoelii sporozoite transmission by infected anopheline mosquitoes. Infect Immun 73: 4363–4369.

29. Pumpuni CB, Mendis G, Beier JC (1997) Plasmodium yoelii sporozoite infectivity varies as a function of sporozoite loads in Anopheles stephensi mosquitoes. J Parasitol 83: 652–655.

30. Kuhler-Kieff B, Majadly F, Besova Z, Moca CP, Gao C, et al. (2010) A bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugates. Proc Natl Acad Sci U S A 107: 1172–1177.

31. Palmi C, Overstreet MG, Guedon JM, Hoiczyk E, Ward C, et al. (2011) Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in mice. Vaccine 29: 1683–1689.

32. Aponte JJ, Ade P, Renom M, Mandomando I, Bassai Q, et al. (2007) Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 370: 1543–1551.

33. Bergmann-Leitner ES, Scheibbohler S, Weiss R, Duncan EH, Leitner WW, et al. (2005) C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria. Int Immunol 17: 245–255.

34. Weiss WR, Jiang CG (2012) Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites. PLoS One 7: e51247.

35. Schofield L, Villagran J, Ferreira A, Schellekens H, Nussenzweig R, et al. (1987) Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 330: 664–666.

36. Weiss WR, Sedequah M, Rouandon RL, Miller LH, Good MF (1983) CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci U S A 80: 573–576.

37. Schulte NJ, Aldhamen YA, Appleford DM, Seregin SS, Kossa Y, et al. (2011) Vaccine platforms combining circumsporozoite protein and potent immune modulators, rEAs or EAT-2, paradoxically result in opposing immune responses. PLoS One 6: e24147.

38. Radoscik K, Rodriguez A, Lenkkeri AA, van der Meer M, Gillsiin G, et al. (2010) The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clin Vaccine Immunol 17: 1687–1694.

39. Tammenga C, Sedequah M, Regis D, Chaang I, Epstein JE, et al. (2011) Adenovirus-5-polyvalent P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS One 6: e25060.

40. Pichyangkul S, Tongtawe P, Kumi-Arb U, Youngvanichit K, Gettyacamin M, et al. (2009) Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system A02A administered alone or concurrently in rhesus monkeys. Vaccine 28: 452–462.

41. Jin R, Lv Z, Chen Q, Quan Y, Zhang H, et al. (2008) Safety and immunogenicity of H5N1 influenza vaccine based on baculovirus surface display system of Bombyx mori. PLoS One 3: e3933.